[Code of Federal Regulations] [Title 21, Volume 1] [Revised as of April 1, 2003] From the U.S. Government Printing Office via GPO Access [CITE: 21CFR5.109] [Page 51] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES PART 5--DELEGATIONS OF AUTHORITY AND ORGANIZATION--Table of Contents Subpart C--Human Drugs; Redelegations of Authority Sec. 5.109 Issuance of written notices concerning patent information, current good manufacturing practices and false or misleading labeling of new drugs. (a) The following officials are authorized to perform all the functions of the Commissioner of Food and Drugs under Sec. 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) regarding the issuance of written notices. (1) The Director, the Deputy Director, and the Directors, Office of Review Management and Office of Pharmaceutical Science, Center for Drug Evaluation and Research (CDER). (2) The Director and Deputy Director, Office of Compliance, CDER. (3) The Director and Deputy Director, Division of Labeling and Nonprescription Drug Compliance, Office of Compliance, CDER. (4) The Director and Deputy Director, Division of Manufacturing and Product Quality, Office of Compliance, CDER. (5) The Director and Deputy Director, Division of Prescription Drug Compliance and Surveillance, Office of Compliance, CDER. (6) The Associate Director for Medical Policy, and the Director and Deputy Director, Division of Scientific Investigations, Office of Medical Policy, CDER. (7) The Director and Deputy Directors, Center for Biologics Evaluation and Research (CBER), the Director and Deputy Directors, Office of Compliance and Biologics Quality (OCBQ), CBER, and the Directors, Division of Case Management, Division of Inspections and Surveillance, and Division of Manufacturing and Product Quality, OCBQ, CBER. (8) The Director and Deputy Directors for Science and for Regulations and Policy, Center for Devices and Radiological Health (CDRH), and the Director and Deputy Directors of the Office of Device Evaluation, CDRH. (9) Regional Food and Drug Directors. (10) District Directors. (b) These officials may not further redelegate this authority.